lifestyle.thriveinsider.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Tenvie Therapeutics, Inc.
Tenvie Therapeutics Announces Dosing of First Subject in Phase 1 Clinical Trial of TNV108, an Allosteric SARM1 inhibitor
April 20, 2026
Tenvie Therapeutics Announces Dosing of First Subject in Phase 1 Clinical Trial of TNV262, a Fully CNS-Penetrant NLRP3 Inhibitor
April 6, 2026
Tenvie Therapeutics Appoints Don O’Sullivan, Ph.D., MBA, as Chief Business Officer
February 18, 2026